Please use this identifier to cite or link to this item: http://hdl.handle.net/10603/4970
Full metadata record
DC FieldValueLanguage
dc.coverage.spatialPharmaceutical Sciencesen_US
dc.date.accessioned2012-10-17T07:18:52Z-
dc.date.available2012-10-17T07:18:52Z-
dc.date.issued2012-10-17-
dc.identifier.urihttp://hdl.handle.net/10603/4970-
dc.description.abstractTwenty one thiazolidin-4-one derivatives were synthesized, purified by chromatographic and non-chromatographic methods. These were characterized through physical constants like melting point, various spectral and chromatographic techniques like, UV scan, IR spectra, NMR spectra, TLC, and LC-MS methods. Since the aim of the study was to evaluate the antidiabetic and hypolipidemic activities of the thiazolidin-4-ones, four compounds were tested using the streptozotocin + nicotinamide induced type-2 diabetes in mouse. All of them reversed the hyperglycemia. Among them, two compounds also reduced the glucose intolerance in an OGTT. All the synthesized 21 thiazolidin-4-ones were tested in an in vitro glucose uptake assay using isolated rat diaphragm. Three compounds showed significant enhancement of glucose uptake by isolated rat diaphragm in presence and absence of insulin. This suggested the potential of these compounds in attenuation of hyperglycemia through enhancement of glucose uptake by peripheral tissue and sensitization of tissue for insulin. In high carbohydrate diet (HCD)-induced insulin resistance mice model, three thiazolidin-4-ones were selected and evaluated. All tested compounds attenuated hyperglycemia, hyperinsulinemia, hypertriglyceridemia, hypercholesterolemia, and glucose intolerance. However, these compounds did not show any effect on hypoadiponectinemia. However, two thiazolidin-4-ones were able to enhance the leptin levels. In HCD model the disturbed liver antioxidants milieu was corrected by all three compounds. Thus, these results showed their anti-oxidant potential to attenuate oxidative stress in diabetes.en_US
dc.format.extent187p.en_US
dc.languageEnglishen_US
dc.relationNo. of references 61en_US
dc.rightsuniversityen_US
dc.titleDevelopment of Thiazolidin 4 one Derivatives for possible Hypolipidaemic and Antidiabetic activitiesen_US
dc.creator.researcherVasantharaju S Gen_US
dc.subject.keywordPharmaceutical Sciencesen_US
dc.description.noteSummary p. 181, Bibliography p. 182-187en_US
dc.contributor.guideKutty, N Gopalanen_US
dc.contributor.guideShenoy, G Gautham-
dc.publisher.placeManipalen_US
dc.publisher.universityManipal Universityen_US
dc.publisher.institutionManipal College of Pharmaceutical Sciencesen_US
dc.date.registeredn.d.en_US
dc.date.completed24/11/2011en_US
dc.date.awarded2011en_US
dc.format.dimensions--en_US
dc.format.accompanyingmaterialNoneen_US
dc.type.degreePh.D.en_US
dc.source.inflibnetINFLIBNETen_US
Appears in Departments:Manipal College of Pharmaceutical Sciences

Files in This Item:
File Description SizeFormat 
01_title.pdfAttached File275.5 kBAdobe PDFView/Open
02_certificate.pdf72.52 kBAdobe PDFView/Open
03_abstract.pdf160.61 kBAdobe PDFView/Open
04_declaration.pdf63.36 kBAdobe PDFView/Open
05_acknowledgement.pdf131.67 kBAdobe PDFView/Open
06_contents.pdf91.15 kBAdobe PDFView/Open
07_list_of_tables.pdf240.6 kBAdobe PDFView/Open
08_list_of_figures.pdf166.38 kBAdobe PDFView/Open
09_abbreviations.pdf229.21 kBAdobe PDFView/Open
10_chapter1.pdf169.22 kBAdobe PDFView/Open
11_chapter 2.pdf191.95 kBAdobe PDFView/Open
12_chapter3.pdf173.03 kBAdobe PDFView/Open
13_chapter 4.pdf4.95 MBAdobe PDFView/Open
14_chapter 5.pdf456.83 kBAdobe PDFView/Open
15_chapter 6.pdf193.12 kBAdobe PDFView/Open
16_chapter 7.pdf902.08 kBAdobe PDFView/Open
17_chapter 8. conclusions, pdf.pdf175.56 kBAdobe PDFView/Open
18_chapter 9. summery, pdf.pdf83.98 kBAdobe PDFView/Open
19_chapter 10. bibliography, pdf.pdf194 kBAdobe PDFView/Open


Items in Shodhganga are protected by copyright, with all rights reserved, unless otherwise indicated.